www.stocktitan.net
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Werewolf Therapeutics (Nasdaq: HOWL) reported second quarter 2026 results and corporate updates, highlighted by a $21.0 million collaboration payment from Jazz Pharmaceuticals Ireland related to the sale of the JZP898 program and the full repayment of its loan with K2 HealthVentures.As of June 30, 2026, Werewolf held $22.0 million in cash and cash equivalents and expects, based on its current operating plan, to fund operations into the second quarter of 2027. Q2 2026 collaboration revenue was $21.0 million, with no collaboration revenue in Q2 2025. Research and development expenses fell to $6.2 million from $13.1 million a year earlier, while general and administrative expenses increased to $7.7 million from $4.4 million.Net income for Q2 2026 was $3.7 million, compared to a net loss of $18.0 million in Q2 2025. Total notes payable declined to zero from $28.2 million at December 31, 2025, and the company continues clinical development of WTX-124 and WTX-330 while pursuing strategic alternatives with Piper Sandler.
